SC 13G
1
basi-13g_20201231.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
BIOANALYTICAL SYSTEMS, INC.
----------------------------------------------------------------------------
(Name of Issuer)
Common Shares
----------------------------------------------------------------------------
(Title of Class of Securities)
09058M103
----------------------------------------------------------------------------
(CUSIP Number)
December 17, 2020
----------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[_] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
=============================================================================
-----------------------------------------------------------------------------
CUSIP NO. 09058M103 13G Page 2 of 8 Pages
-----------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).
Renaissance Technologies LLC 26-0385758
-----------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
(a) [_]
(b) [_]
-----------------------------------------------------------------------------
(3) SEC USE ONLY
-----------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF SHARES 481,476
BENEFICIALLY OWNED _____________________________
BY EACH REPORTING
PERSON WITH: (6) SHARED VOTING POWER
0
_____________________________
(7) SOLE DISPOSITIVE POWER
600,065
_____________________________
(8) SHARED DISPOSITIVE POWER
0
______________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
600,065
------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.43 %
------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
Page 2 of 8 pages
=============================================================================
Page 3 of 8 pages
-----------------------------------------------------------------------------
CUSIP NO. 09058M103 13G Page 3 of 8 Pages
-----------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734
-----------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) [_]
(b) [_]
-----------------------------------------------------------------------------
(3) SEC USE ONLY
-----------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF SHARES 481,476
BENEFICIALLY OWNED _____________________________
BY EACH REPORTING
PERSON WITH: (6) SHARED VOTING POWER
0
_____________________________
(7) SOLE DISPOSITIVE POWER
600,065
_____________________________
(8) SHARED DISPOSITIVE POWER
0
_____________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
600,065
-----------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
-----------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.43 %
-----------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC
Page 3 of 8 pages
=============================================================================
-----------------------------------------------------------------------------
CUSIP NO. 09058M103 13G Page 4 of 8 Pages
-----------------------------------------------------------------------------
Item 1.
(a) Name of Issuer
BIOANALYTICAL SYSTEMS, INC.
(b) Address of Issuer's Principal Executive Offices.
2701 KENT AVENUE, WEST LAFAYETTE, INDIANA 47906
Item 2.
(a) Name of Person Filing:
This Schedule 13G is being filed by Renaissance Technologies LLC
("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b) Address of Principal Business Office or, if none, Residence.
The principal business address of the reporting persons is:
800 Third Avenue
New York, New York 10022
(c) Citizenship.
RTC is a Delaware limited liability company, and
RTHC is a Delaware corporation.
(d) Title of Class of Securities.
Common Shares
(e) CUSIP Number.
09058M103
Page 4 of 8 pages
=============================================================================
Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b)
or (c),check whether the person filing is a:
(a) [_] Broker or dealer registered under section 15 of the Act.
(b) [_] Bank as defined in section 3(a)(6) of the Act.
(c) [_] Insurance Company as defined in section 3(a)(19) of the Act.
(d) [_] Investment Company registered under section 8 of the Investment
Company Act.
(e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E).
(f) [_] Employee Benefit Plan or Endowment Fund in accordance with
Sec. 240.13d-1(b)(1)(ii)(F).
(g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G).
(h) [_] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act.
(i) [_] A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940.
(j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
(a) Amount beneficially owned.
RTC: 600,065 shares
RTHC: 600,065 shares, comprising the shares beneficially owned
by RTHC, because of RTHC's majority ownership of RTC.
(b) Percent of Class.
RTC: 5.43 %
RTHC: 5.43 %
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote:
RTC: 481,476
RTHC: 481,476
(ii) Shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of:
RTC: 600,065
RTHC: 600,065
(iv) Shared power to dispose or to direct the disposition of:
RTC: 0
RTHC: 0
Page 5 of 8 pages
=============================================================================
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following: [_]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Certain funds and accounts managed by RTC have the right to receive
dividends and proceeds from the sale of the securities which are
the subject of this report.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of a Group.
Not applicable
Page 6 of 8 pages
=============================================================================
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: February 10, 2021
Renaissance Technologies LLC
By: /s/ James S. Rowen
Chief Operating Officer
Renaissance Technologies Holdings Corporation
By: /s/ James S. Rowen
Vice President
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Page 7 of 8 Pages
==============================================================================
EXHIBIT 99.1
AGREEMENT REGARDING JOINT FILING
UNDER RULE 13D-1(K) OF THE EXCHANGE ACT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, each of the undersigned agrees to the filing on behalf of each
of a Statement on Schedule 13G, and all amendments thereto, with respect to
the Common Shares of
BIOANALYTICAL SYSTEMS, INC.
Date: February 10, 2021
Renaissance Technologies LLC
By: /s/ James S. Rowen
Chief Operating Officer
Renaissance Technologies Holdings Corporation
By: /s/ James S. Rowen
Vice President
Page 8 of 8 Pages
WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, that same day. Effective Monday, March 22, 2021, The Company’s common shares will trade under the ti
WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology. Safety pharmacology evaluations are critical for assessing the impact of drug candidates. By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and ce
WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step fo
WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice
